C0031638||phosphodiesterase 10A inhibitor
C0237798||non-human primates
C0036341||schizophrenia
C0879626||side effect profile
C0036341||Schizophrenia
C1457887||symptoms
C0004782||alterations in basal ganglia-cortical networks
C0028631||cyclic nucleotides
C0001455||cAMP
C0018338||cGMP
C0037080||signaling pathways
C0031638||Phosphodiesterase 10A (PDE10A) inhibitors
C1611640||therapeutic agents
C0036341||schizophrenia
C2613288||regulation of cAMP
C2612051||cGMP
C0010097||striatum
C1447737||Phosphodiesterase 10A
C0037080||signaling mechanisms
C0392335||cognitive function
C0237798||non-human primates
C0237798||non-human primates
C0031638||PDE10A inhibitor
C0031638||FRM-6308
C1447737||human recombinant PDE10A
C0243095||behavioral effects
C0031638||FRM-6308
C0024400||rhesus monkeys
C4228195||standardized motor disability scale
C0033147||primates
C0556033||motor tasks
C0031638||FRM-6308
C2315783||[(18)F]-fluorodeoxyglucose PET imaging
C0031638||FRM-6308
C0237798||non-human primates
C0046056||FDG
C0010097||striatum
C1181303||cortical
C0235195||sedation
C0427086||occasional involuntary movements
C0743284||tolerance after repeated exposures
C0031638||FRM-6308
C1320678||adequate pharmacological profile
C0008976||clinical trials
C3179403||antipsychotic efficacy
C1447737||Phosphodiesterase 10A
C0036341||schizophrenia